JERSEY CITY, N.J., April 15, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, La., Apr. 15-18, 2024.
JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADICAVA ORS Priority Review and Fast Track designations.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced that the US Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for Radicava ORS (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA’s Orphan Drug programme is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the US Previously, the FDA granted Radicava ORS Priority Review and Fast Track designations.
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research
JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
JERSEY CITY, N.J., Oct. 16, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.
JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.